Clinical Trial

Self-compassion and Bipolar Disorder

Study acronym: COMPASS-TB
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated June 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
Currently, pharmacotherapy is central in the management of bipolar disorder (BD), but does not guarantee satisfactory results for many patients. Existing psychotherapies, notably cognitive-behavioral therapy (CBT), show some effectiveness, but do not target the mechanisms that maintain the disorder. Indeed, people with BD present a low level of self-compassion, suffer from comorbidities (e.g. anxiety, depression), and have a high level of emotional dysregulation, which can contribute to increasing the risk of relapse and mood instability. In this context, it has been suggested that interventions targeting self-compassion could reduce BD psychopathology and strengthen emotional regulation skills. Two psychological therapies targeting self-compassion could be promising in the treatment of BD: Compassion-Based Therapy (CBT) and Cognitive Therapy focused on Mental Imagery (mTCI). These approaches partly emphasize compassionate mental imagery to promote self-soothing and emotion management skills. Studies on the feasibility and effectiveness of CBT and mTCI in the context of BD are few in number, and do not focus on their impact on emotional regulation abilities. Evaluating these therapies could lead to the development of more specific and effective interventions for people with TB.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06497868
Lead Sponsor University Hospital, Strasbourg, France
Conditions Bipolar Disorder
Enrollment 10 participants
Start Date 2024-06-20
Primary Completion 2025-06-20 (estimated)
Study Completion 2025-06-20 (estimated)
Updated on ClinicalTrials.gov 2024-07-12